ONXEO (EPA:ALONX) | WebDisclosure

Basculer en Français

11182	Companies
247271	Keywords
175111	Articles
133582	Press releases

Home
Companies
ONXEO

PRESS RELEASE

published on 06/05/2024 at 07:00, 2 years 4 months ago

Inside Information / Other news releases
Valerio Therapeutics reports successful Combined General Meeting with 48.1% quorum, adopting all resolutions. Consolidated vote results and meeting minutes to be available on the Company's website

Euronext Growth Paris Biotechnology General Meeting Valerio Therapeutics DDR Drugs
PRESS RELEASE

published on 06/05/2024 at 07:00, 2 years 4 months ago

Informations privilégiées / Autres communiqués
Valerio Therapeutics a tenu son assemblée générale mixte avec succès, adoptant toutes les résolutions du Conseil d'Administration. La Société se spécialise dans le développement de médicaments innovants ciblant les mécanismes de réponse aux dommages de l’ADN tumoral et les oncogènes pilotes

Biotechnologie Assemblée Générale Cancer Valerio Therapeutics ADN Tumoral
BRIEF

published on 05/22/2024 at 20:51, 2 years 4 months ago

Valerio Therapeutics fait progresser l'essai clinique VIO-01 avec des résultats positifs

Essai Clinique Développement De Médicaments VIO-01 Valerio Thérapeutique Tumeurs Solides
BRIEF

published on 05/22/2024 at 20:51, 2 years 4 months ago

Valerio Therapeutics Advances VIO-01 Clinical Trial with Positive Results

Drug Development Solid Tumors Clinical Trial Valerio Therapeutics VIO-01
PRESS RELEASE

published on 05/22/2024 at 20:46, 2 years 4 months ago

Informations privilégiées / Autres communiqués
Valerio Therapeutics annonce l'achèvement du dosage de la première cohorte de sujets dans son essai clinique de phase 1/2 VIO-01 pour traiter les tumeurs solides sans événements indésirables graves rapportés

Biotechnologie Essai Clinique Valerio Therapeutics VIO-01 Tumeurs Solides
PRESS RELEASE

published on 05/22/2024 at 20:46, 2 years 4 months ago

Inside Information / Other news releases
Valerio Therapeutics completes dosing for first cohort of subjects in Phase 1/2 VIO-01 trial for solid tumors, showing encouraging tolerability. Phase 1b aims to determine recommended dose in selected solid tumors

Solid Tumors Valerio Therapeutics VIO-01 Trial Phase 1/2 DNA Damage Response
BRIEF

published on 04/30/2024 at 23:19, 2 years 5 months ago

Valerio Therapeutics Reports 2023 Fiscal Year Results and Clinical Updates

Biotechnology Clinical Trials Financial Results 2023 Valerio Therapeutics VIO-01
BRIEF

published on 04/30/2024 at 23:19, 2 years 5 months ago

Valerio Therapeutics publie ses résultats pour l'exercice 2023 et des mises à jour cliniques

Biotechnologie Résultats Financiers 2023 Essais Cliniques VIO-01 Valerio Thérapeutique
PRESS RELEASE

published on 04/30/2024 at 23:14, 2 years 5 months ago

Rapports financiers et d'audit annuels / Modalités de mise à disposition du rapport financier annuel
Valerio Therapeutics publie ses résultats financiers 2023 et les avancées de son développement clinique. Une trésorerie de 6,8 millions d'euros au 31 décembre 2023 assure la visibilité financière jusqu'à fin 2024

Résultats Financiers Biotechnologie Trésorerie Développement Clinique Valerio Therapeutics
PRESS RELEASE

published on 04/30/2024 at 23:14, 2 years 5 months ago

Annual financial and audit reports / Terms of availability of the annual financial report
Valerio Therapeutics reports full year 2023 financial results and provides clinical development updates. The company's cash position is €6.8 million as of December 31, 2023, ensuring financial visibility until Q4 2024

Financial Results Cash Position 2023 Clinical Development Valerio Therapeutics

Accesswire

Published on 10/15/2026 at 16:10, 1 hour 51 minutes ago

North Shore Announces Extension to Falcon Property Option Agreement and Resource Stock Digest Engagement
Published on 10/15/2026 at 15:15, 2 hours 46 minutes ago

Gold Terra to Host Community Town Hall Meeting in Yellowknife on October 21, 2026
Published on 10/15/2026 at 14:31, 3 hours 30 minutes ago

First Breach to Present at the 20th Annual LD Micro Main Event
Published on 10/15/2026 at 14:05, 3 hours 56 minutes ago

Innodata to Report Third Quarter 2026 Results
Published on 10/15/2026 at 14:00, 4 hours 1 minute ago

Tectonic Metals Drills 2.41 g/t Au over 59.44 metres, Including 11.82 g/t Au over 10.67 metres and 39.96 g/t Au over 3.05 metres at Alpha Bowl, Flat Gold Project, Alaska

View all ACCESSWIRE

EQS Group

Published on 10/15/2026 at 17:24, 37 minutes ago

Cairn Homes Plc: Holding(s) in Company
Published on 10/15/2026 at 16:55, 1 hour 6 minutes ago

Verlingue consolidates its international offering by integrating Verlingue Portugal into the WBN network
Published on 10/15/2026 at 16:50, 1 hour 11 minutes ago

Good Brands AG: Portfolio under management grows to EUR 139 million in LTM revenue – sharpened focus on high-growth investments
Published on 10/15/2026 at 16:33, 1 hour 28 minutes ago

EQS-Adhoc: Good Brands AG: Portfolio Clean-up – Impairment of Investments
Published on 10/15/2026 at 16:05, 1 hour 56 minutes ago

webhotelier | primalres rebrands as revplus, entering the era of a unified ecosystem

Les Echos

Published on 10/15/2026 at 17:45, 16 minutes ago

DECLARATION D’ACTIONS ET DE DROITS DE VOTE
Published on 10/15/2026 at 17:45, 16 minutes ago

DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 10/15/2026 at 17:45, 16 minutes ago

Entech remporte un contrat EPC portant sur une centrale de stockage d’énergie par batterie (BESS) de 180 MWh
Published on 10/15/2026 at 17:45, 16 minutes ago

VOGO : Résultats semestriels 2026.
Published on 10/15/2026 at 17:45, 16 minutes ago

VOGO : H1 2026 results.

View all LES ECHOS COMFI WIRE